PMV Pharmaceuticals Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“In preclinical animal studies, PC14586 exhibited fast absorption and a durable plasma exposure, which resulted in robust target engagement that correlated with compound exposure levels. Target engagement was demonstrated by the decrease in mutant p53 Y220C and the increase in the wild-type conformation.” (Page 128) Read the full document
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company’s lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Company Website: https://www.pmvpharma.com